Rapporto sull’analisi delle dimensioni del mercato e dell’analisi delle quote della neuropatia periferica indotta da chemioterapia | Previsioni 2031

  • Report Code : TIPRE00028941
  • Category : Pharmaceuticals
  • Status : Published
  • No. of Pages : 151
Buy Now

[Rapporto di ricerca] Si prevede che il mercato della neuropatia periferica indotta da chemioterapia raggiungerà 1.174,26 milioni di dollari entro il 2028 rispetto a 813,48 milioni di dollari nel 2021; si prevede di registrare un CAGR di  5,4% dal 2021 al 2028.

La neuropatia periferica indotta dalla chemioterapia è uno degli effetti collaterali più frequenti causati dagli agenti antineoplastici. Clinicamente si tratta di una neuropatia prevalentemente sensoriale che può essere accompagnata da alterazioni motorie e autonomiche di varia intensità e durata. A causa della sua elevata prevalenza tra i pazienti affetti da cancro, la neuropatia periferica indotta dalla chemioterapia costituisce un grave problema sia per i malati di cancro che per i sopravvissuti, nonché per i loro operatori sanitari, soprattutto perché, al momento, non esiste un unico metodo efficace per prevenirla; inoltre, le possibilità di trattare questa sindrome sono limitate.

Approfondimenti strategici

Il rapporto offre approfondimenti e analisi approfondite del mercato della neuropatia periferica indotta da chemioterapia (CIPN) sottolineando le tendenze del mercato, progressi tecnologici e dinamiche di mercato. Fornisce inoltre l’analisi del panorama competitivo dei principali attori del mercato in tutto il mondo. Inoltre, il rapporto include l’impatto della pandemia COVID-19 sul mercato della neuropatia periferica indotta dalla chemioterapia in tutte le regioni. La pandemia ha creato sia una crisi sanitaria pubblica che una crisi economica in tutto il mondo. Il mercato globale della neuropatia periferica indotta dalla chemioterapia prima della pandemia era in costante crescita a causa della regolarità dello screening, delle consultazioni e dei trattamenti per il cancro. La prima ondata di COVID-19 ha interrotto le consultazioni, i follow-up e gli screening dei casi oncologici. Inoltre, le interruzioni negli studi clinici e nella fornitura di farmaci ai pazienti durante la fase iniziale della pandemia di COVID-19 hanno avuto un impatto sulle aree più cruciali del mercato della neuropatia periferica indotta dalla chemioterapia. Uno spostamento dell’attenzione sul trattamento tempestivo del COVID-19 ha portato a negligenza nei confronti di varie altre condizioni mediche. Inoltre, la diminuzione del rilevamento di casi di cancro e delle sessioni di chemioterapia per il trattamento ha ostacolato la domanda di diagnosi e trattamenti di neuropatia periferica indotta dalla chemioterapia.  

Regioni redditizie per il mercato della neuropatia periferica indotta da chemioterapia


Approfondimenti di mercato
L'aumento della prevalenza del cancro determina la crescita del mercato della neuropatia periferica indotta da chemioterapia< /h3>

Il cancro è una delle principali cause di morte in tutto il mondo. Secondo l’Organizzazione Mondiale della Sanità (OMS), nel 2019 il cancro è stato segnalato come la prima causa di morte tra le persone di età inferiore a 70 anni in 183 paesi e la quarta causa di morte tra la popolazione di tutte le età in 123 paesi in tutto il mondo. Inoltre, secondo i dati pubblicati dall'OMS nel marzo 2021, diversi tipi di cancro hanno causato circa 10 milioni di decessi nel 2020.

Forme di cancro più diffuse al mondo, 2020

La crescente prevalenza del cancro ha creato un peso sui sistemi sanitari di tutto il mondo, oltre a rafforzare la domanda di chemioterapia. La neuropatia periferica indotta dalla chemioterapia è un effetto avverso comune dei farmaci antitumorali neurotossici, come i farmaci derivati del platino (cisplatino e oxaliplatino), i veleni del fuso [taxani (paclitaxel e docetaxel), gli alcaloidi della vinca, vincristina, epotiloni ed eribulina], bortezomib, e talidomide. L'elevata prevalenza della neuropatia periferica indotta dalla chemioterapia solleva preoccupazioni per i malati di cancro, i sopravvissuti e i loro operatori sanitari, soprattutto perché non esiste un unico modo efficace per prevenire questa condizione.

In uno studio condotto da "The Journal of the International Association for the Study of Pain,” la prevalenza della neuropatia periferica indotta dalla chemioterapia è stata segnalata al 68,1% (57,7-78,4 se misurata nel primo mese dopo la chemioterapia, al 60,0% (36,4-81,6) nel terzo mese e al 30,0% (6,4-53,5) nel sesto mese o più tardi. Pertanto, la crescente incidenza della neuropatia periferica indotta dalla chemioterapia insieme alla crescente prevalenza del cancro stimola la crescita del mercato della neuropatia periferica indotta dalla chemioterapia.

Approfondimenti basati sulla classe dei farmaci

< p>In base alla classe di farmaci, il mercato della neuropatia periferica indotta da chemioterapia è segmentato in steroidi, antidepressivi, antiepilettici e narcotici. Nel 2021, il segmento degli steroidi deteneva la quota maggiore del mercato. Si prevede che il segmento degli antiepilettici registrerà il CAGR più rapido, pari al 6,2% durante il periodo di previsione.  

Mercato della neuropatia periferica indotta da chemioterapia, per prodotto - 2020 e 2028

Basato sul canale di distribuzione Approfondimenti

In base al canale di distribuzione, il mercato della neuropatia periferica indotta dalla chemioterapia è segmentato in farmacia ospedaliera, farmacia al dettaglio e farmacia online. Nel 2021, il segmento delle farmacie ospedaliere deteneva la quota maggiore del mercato. Inoltre, si prevede che il segmento delle farmacie al dettaglio registrerà il CAGR più elevato, pari al 5,9% nel periodo dal 2021 al 2028.

Gli operatori del mercato della neuropatia periferica indotta da chemioterapia (CIPN) si concentrano sull'adozione di strategie organiche come il lancio del prodotto e l'espansione verso espandere la propria presenza e il portafoglio di prodotti in tutto il mondo, nonché soddisfare le crescenti richieste.

Per area geografica

In base all'area geografica, il mercato della neuropatia periferica indotta da chemioterapia è segmentato in Nord America (Stati Uniti , Canada e Messico), Europa (Regno Unito, Germania, Francia, Italia, Spagna e resto dell'Europa), Asia Pacifico (Cina, Giappone, India, Australia, Corea del Sud e resto dell'Asia Pacifico), Medio Oriente e altri ; Africa (Emirati Arabi Uniti, Arabia Saudita, Sud Africa e resto del Medio Oriente e dell'Africa) e Sud e Africa. America centrale (Brasile, Argentina e resto dell'America meridionale e centrale).

Profili aziendali

  • Regenacy Pharmaceuticals, Inc.
  • Asahi Kasei Pharma Corporation
  • Novaremed
  • Makscientific, Llc
  • Wex Pharmaceuticals Inc.
  • Sova Pharmaceuticals, Inc.
  • Kineta, Inc.
  • Aptinyx Inc.
  • Apexian Pharmaceuticals, Inc.
  • Winsantor, Inc.
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


What is the chemotherapy induced peripheral neuropathy market?

Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most frequent side effects caused by antineoplastic agents. Clinically, CIPN is a mostly sensory neuropathy that may be accompanied by motor and autonomic changes of varying intensity and duration. Due to its high prevalence among cancer patients, CIPN constitutes a major problem for both cancer patients and survivors as well as for their health care providers, especially because, at the moment, there is no single effective method of preventing CIPN; moreover, the possibilities of treating this syndrome are very limited.

What are the driving factors for the chemotherapy induced peripheral neuropathy market across the country?

The factors that are driving and restraining factors that will affect the chemotherapy induced peripheral neuropathy market in the coming years. Major factors driving the market growth include the increasing prevalence of cancer and increasing preference for chemotherapy. Additionally, the growing clinical trials for chemotherapeutic drugs is likely to emerge as a significant future trend in the market during the forecast period. However, lack of consolidated guidelines for chemotherapy hamper the chemotherapy induced peripheral neuropathy market growth.

Which segment is dominating the chemotherapy induced peripheral neuropathy market?

The chemotherapy induced peripheral neuropathy market, by drug class, is bifurcated into steroids, antidepressants, anti-seizure medicines, and narcotics. In 2021, the steroids segment held the largest share of the market. The anti-seizure medicines segment of the chemotherapy induced peripheral neuropathy market is expected to witness growth in its demand at the fastest CAGR during the forecast period.

Who are the major players in market the chemotherapy induced peripheral neuropathy market?

The chemotherapy induced peripheral neuropathy market majorly consists of the players such as Regenacy Pharmaceuticals, Inc, Asahi Kasei Pharma Corporation., Novaremed, Makscientific, Llc, Wex Pharmaceuticals Inc., Sova Pharmaceuticals, Inc., Kineta, Inc., Aptinyx Inc., Apexian Pharmaceuticals, Inc., and Winsantor, Inc. amongst others.

The List of Companies - Chemotherapy Induced Peripheral Neuropathy Market

  1. REGENACY PHARMACEUTICALS, INC
  2. ASAHI KASEI PHARMA CORPORATION
  3. NOVAREMED
  4. MAKSCIENTIFIC, LLC
  5. WEX PHARMACEUTICALS INC
  6. SOVA PHARMACEUTICALS, INC
  7. KINETA, INC.
  8. APTINYX INC.
  9. APEXIAN PHARMACEUTICALS, INC.
  10. WINSANTOR, INC

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports